Ethan Allen (ETD) delivered earnings and revenue surprises of 23.08% and -0.72%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Ethan Allen (ETD) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 23.08%. A quarter ago, it was expected that this home furnishings company would post earnings of $0.74 per share when it actually produced earnings of $0.74, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Ethan Allen, which belongs to the Zacks Retail - Home Furnishings industry, posted revenues of $182.33 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 0.72%. This compares to year-ago revenues of $151.06 million. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Ethan Allen shares have added about 17.7% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Ethan Allen?While Ethan Allen has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Ethan Allen was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.67 on $186.1 million in revenues for the coming quarter and $2.70 on $748.45 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Retail - Home Furnishings is currently in the top 17% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ethan Allen Interiors Inc. (ETD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Align Technology (ALGN) delivered earnings and revenue surprises of 13.89% and 5.67%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Align Technology (ALGN) came out with quarterly earnings of $2.87 per share, beating the Zacks Consensus Estimate of $2.52 per share. This compares to earnings of $2.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.89%. A quarter ago, it was expected that this maker of the Invisalign tooth-straightening system would post earnings of $2.52 per share when it actually produced earnings of $3.04, delivering a surprise of 20.63%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.Align Technology, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $1.02 billion for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 5.67%. This compares to year-ago revenues of $734.14 million. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Align Technology shares have added about 11% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Align Technology?While Align Technology has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Align Technology was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.78 on $1.05 billion in revenues for the coming quarter and $10.98 on $3.91 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Sleep Number (SNBR) delivered earnings and revenue surprises of 54.17% and 12.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Sleep Number (SNBR) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $1.44 per share. This compares to earnings of $1.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 54.17%. A quarter ago, it was expected that this seller of beds, mattresses and bedding products would post earnings of $1.11 per share when it actually produced earnings of $0.88, delivering a surprise of -20.72%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Sleep Number, which belongs to the Zacks Furniture industry, posted revenues of $640.39 million for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 12.99%. This compares to year-ago revenues of $531.16 million. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Sleep Number shares have added about 10.9% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Sleep Number?While Sleep Number has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Sleep Number was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.40 on $674.35 million in revenues for the coming quarter and $7.18 on $2.29 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Furniture is currently in the bottom 4% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sleep Number Corporation (SNBR): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Alerus (ALRS) delivered earnings and revenue surprises of 48.00% and 7.55%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Alerus (ALRS) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.99 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 48%. A quarter ago, it was expected that this company would post earnings of $0.56 per share when it actually produced earnings of $0.66, delivering a surprise of 17.86%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Alerus, which belongs to the Zacks Financial - Miscellaneous Services industry, posted revenues of $57.17 million for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 7.55%. This compares to year-ago revenues of $67.02 million. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Alerus shares have added about 15.1% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Alerus?While Alerus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Alerus was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.50 on $51.81 million in revenues for the coming quarter and $2.49 on $225.82 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial - Miscellaneous Services is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alerus Financial (ALRS): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Software has infinite capabilities because it consumes neither time or space. In 2017 I published one of my most important investment strategy pieces that I called The Technology Super Cycle.You can see a 2018 video and article version via that link, where I answer this burning puzzle: why is inflation absent and productivity "hidden?"The two main solutions to that puzzle are still very relevant to what you see happening in the most important sector of the economy.In the thesis, I said you had to be a buyer of NVIDIA NVDA for the future they were building with GPU platforms and CUDA stacks of software capabilities that digital engineers, data analysts, and scientists had to have.And this was before I'd ever heard of Cathie Wood and her similar takes on long-tail "disruptive innovation."But lately, as I immerse myself in the exploding world of private FinTech companies, I have begun to see another driving force."Where do unicorns come from? Imagine 10,000 VCs chasing twice as many fintech companies."That's what I proposed in my Cook's Kitchen from two weeks ago...Unicorn Stampede: How FinTech Innovation and VC Warchests Fuel MarketsIn the video that accompanies this article, I review the Pinterest PINS and PayPal PYPL unfolding drama we discussed last week.PINS shares today are filling the October 2020 gap up from $45 on the deal rumors getting scuttled. In the video, I tell you who a big seller has been. Meanwhile PYPL continues to plummet into my $220-240 "buy zone."I also reiterate my "buy zone" for Shopify SHOP inside $1240-80, with starter positions recommended under $1350 ahead of their earnings report on Thursday.Call With CookerIf you came here from the YouTube link, I have your code/instructions to enter the "Call with Cooker" drawing: #TechSuperCycleJust go to Twitter and do the following...1. Follow me @KevinBCook2. Like and ReTweet my pinned Tweet with the NVIDIA graphicSpeaking of Twitter TWTR, in a very meta-social event, I attended this morning's Space chat with the CFO, Ned Segal. Dude was super chill under pressure from annoying analysts who kept trying to get him to parse his KPIs for the mDAU metric (monetizable daily active users).Segal is a model for any corporate executive doing media interviews. He just naturally calms the room and the fire-breathers by never getting defensive or frustrated and just explaining his goals while trying to answer the questions.And apparently in his CNBC interview this morning, he said "Bitcoin is going to be a great way for us to facilitate commerce on Twitter." That's very interesting.I was on another Twitter Space last night where a bunch of "new money/digital gold" theorists were debating @Jack's recent post about "hyper-inflation is coming."When you go to my Twitter feed, you'll see those Space posts and you can check out the other things I've posted on Segal and FinTech, including the link to the Plaid report.Thanks for joining me in the Kitchen!Disclosure: I own shares of NVDA, PINS, and SQ for the Zacks TAZR Trader portfolio. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NVIDIA Corporation (NVDA): Free Stock Analysis Report Twitter, Inc. (TWTR): Free Stock Analysis Report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Shopify Inc. (SHOP): Free Stock Analysis Report Pinterest, Inc. (PINS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

CyrusOne (CONE) delivered FFO and revenue surprises of 3.03% and 4.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? CyrusOne (CONE) came out with quarterly funds from operations (FFO) of $1.02 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to FFO of $0.96 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an FFO surprise of 3.03%. A quarter ago, it was expected that this data center operator would post FFO of $0.98 per share when it actually produced FFO of $1, delivering a surprise of 2.04%.Over the last four quarters, the company has surpassed consensus FFO estimates four times.CyrusOne, which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $304.1 million for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 4.21%. This compares to year-ago revenues of $262.8 million. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.CyrusOne shares have added about 11.4% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for CyrusOne?While CyrusOne has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.Ahead of this earnings release, the estimate revisions trend for CyrusOne was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus FFO estimate is $1.02 on $295.29 million in revenues for the coming quarter and $4.01 on $1.17 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CyrusOne Inc (CONE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Cognizant (CTSH) delivered earnings and revenue surprises of 0.95% and 0.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Cognizant (CTSH) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.95%. A quarter ago, it was expected that this information technology consulting and outsourcing firm would post earnings of $0.96 per share when it actually produced earnings of $0.99, delivering a surprise of 3.13%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Cognizant, which belongs to the Zacks Business - Software Services industry, posted revenues of $4.74 billion for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 0.34%. This compares to year-ago revenues of $4.24 billion. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Cognizant shares have lost about 3.9% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Cognizant?While Cognizant has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Cognizant was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.02 on $4.75 billion in revenues for the coming quarter and $4.05 on $18.47 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Business - Software Services is currently in the bottom 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cognizant Technology Solutions Corporation (CTSH): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Goosehead (GSHD) delivered earnings and revenue surprises of 50.00% and 5.97%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Goosehead Insurance (GSHD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this insurance company would post earnings of $0.18 per share when it actually produced earnings of $0.13, delivering a surprise of -27.78%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Goosehead, which belongs to the Zacks Insurance - Multi line industry, posted revenues of $41.68 million for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 5.97%. This compares to year-ago revenues of $32.02 million. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Goosehead shares have added about 23.5% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Goosehead?While Goosehead has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Goosehead was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.25 on $42.72 million in revenues for the coming quarter and $0.53 on $151.48 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Insurance - Multi line is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Goosehead Insurance (GSHD): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Allison Transmission (ALSN) delivered earnings and revenue surprises of 0.00% and -3.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Allison Transmission (ALSN) came out with quarterly earnings of $0.89 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.68 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this automatic transmission maker would post earnings of $0.92 per share when it actually produced earnings of $1.01, delivering a surprise of 9.78%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Allison Transmission, which belongs to the Zacks Automotive - Original Equipment industry, posted revenues of $567 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 3.56%. This compares to year-ago revenues of $532 million. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Allison Transmission shares have lost about 22.3% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Allison Transmission?While Allison Transmission has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Allison Transmission was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.88 on $595.22 million in revenues for the coming quarter and $3.85 on $2.36 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Automotive - Original Equipment is currently in the bottom 6% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Allison Transmission Holdings, Inc. (ALSN): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Ford Motor Company (F) delivered earnings and revenue surprises of 82.14% and 4.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Ford Motor Company (F) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.65 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 82.14%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced earnings of $0.13, delivering a surprise of 218.18%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.Ford Motor Company, which belongs to the Zacks Automotive - Domestic industry, posted revenues of $33.2 billion for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 4.62%. This compares to year-ago revenues of $34.71 billion. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Ford Motor Company shares have added about 81.3% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Ford Motor Company?While Ford Motor Company has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Ford Motor Company was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.20 on $38.61 billion in revenues for the coming quarter and $1.56 on $123.44 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Automotive - Domestic is currently in the bottom 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ford Motor Company (F): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Flowserve (FLS) delivered earnings and revenue surprises of -27.50% and -3.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Flowserve (FLS) came out with quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -27.50%. A quarter ago, it was expected that this company that makes pumps, valves and other parts for the oil and gas industries would post earnings of $0.43 per share when it actually produced earnings of $0.37, delivering a surprise of -13.95%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Flowserve, which belongs to the Zacks Manufacturing - General Industrial industry, posted revenues of $866.12 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 3.40%. This compares to year-ago revenues of $924.3 million. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Flowserve shares have added about 0.5% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Flowserve?While Flowserve has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Flowserve was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.53 on $978.87 million in revenues for the coming quarter and $1.59 on $3.63 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Manufacturing - General Industrial is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Flowserve Corporation (FLS): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Duke Realty (DRE) delivered FFO and revenue surprises of 4.55% and 0.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Duke Realty (DRE) came out with quarterly funds from operations (FFO) of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to FFO of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an FFO surprise of 4.55%. A quarter ago, it was expected that this real estate development company would post FFO of $0.43 per share when it actually produced FFO of $0.44, delivering a surprise of 2.33%.Over the last four quarters, the company has surpassed consensus FFO estimates two times.Duke Realty, which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $256.82 million for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 0.04%. This compares to year-ago revenues of $235.39 million. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.Duke Realty shares have added about 39.1% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Duke Realty?While Duke Realty has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.Ahead of this earnings release, the estimate revisions trend for Duke Realty was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus FFO estimate is $0.45 on $256.7 million in revenues for the coming quarter and $1.72 on $1.06 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Duke Realty Corporation (DRE): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Noodles & Co. (NDLS) delivered earnings and revenue surprises of 33.33% and -0.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Noodles & Co. (NDLS) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this restaurant chain would post earnings of $0.11 per share when it actually produced earnings of $0.10, delivering a surprise of -9.09%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Noodles & Co.Which belongs to the Zacks Retail - Restaurants industry, posted revenues of $125.13 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 0.11%. This compares to year-ago revenues of $105.98 million. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Noodles & Co. Shares have added about 60.3% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Noodles & Co.While Noodles & Co. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Noodles & Co. Was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.08 on $123.68 million in revenues for the coming quarter and $0.24 on $484.16 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Retail - Restaurants is currently in the bottom 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Noodles & Company (NDLS): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Twilio (TWLO) delivered earnings and revenue surprises of 106.67% and 8.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Twilio (TWLO) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 106.67%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.11, delivering a surprise of 21.43%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.Twilio, which belongs to the Zacks Internet - Software industry, posted revenues of $740.18 million for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 8.82%. This compares to year-ago revenues of $447.97 million. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Twilio shares have added about 4.6% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Twilio?While Twilio has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Twilio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.09 on $737.44 million in revenues for the coming quarter and -$0.28 on $2.68 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the bottom 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Twilio Inc. (TWLO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Cincinnati Financial (CINF) delivered earnings and revenue surprises of 11.30% and 11.80%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Cincinnati Financial (CINF) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.30%. A quarter ago, it was expected that this insurer would post earnings of $0.99 per share when it actually produced earnings of $1.79, delivering a surprise of 80.81%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.Cincinnati Financial, which belongs to the Zacks Insurance - Property and Casualty industry, posted revenues of $1.86 billion for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 11.80%. This compares to year-ago revenues of $1.69 billion. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Cincinnati Financial shares have added about 40.8% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Cincinnati Financial?While Cincinnati Financial has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Cincinnati Financial was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.34 on $1.68 billion in revenues for the coming quarter and $5.23 on $7.86 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Insurance - Property and Casualty is currently in the bottom 17% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cincinnati Financial Corporation (CINF): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Brightcove (BCOV) delivered earnings and revenue surprises of 150.00% and 2.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Brightcove (BCOV) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 150%. A quarter ago, it was expected that this internet video streaming service company would post earnings of $0.03 per share when it actually produced earnings of $0.11, delivering a surprise of 266.67%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.Brightcove, which belongs to the Zacks Internet - Content industry, posted revenues of $52.16 million for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 2.43%. This compares to year-ago revenues of $49.08 million. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Brightcove shares have lost about 33.9% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Brightcove?While Brightcove has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Brightcove was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.07 on $55.21 million in revenues for the coming quarter and $0.35 on $212.43 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Content is currently in the bottom 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Brightcove Inc. (BCOV): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Conmed (CNMD) delivered earnings and revenue surprises of 3.90% and -2.51%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Conmed (CNMD) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.90%. A quarter ago, it was expected that this medical technology company would post earnings of $0.62 per share when it actually produced earnings of $0.71, delivering a surprise of 14.52%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.Conmed, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $248.83 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 2.51%. This compares to year-ago revenues of $237.84 million. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Conmed shares have added about 28.1% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Conmed?While Conmed has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Conmed was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.07 on $280.06 million in revenues for the coming quarter and $3.19 on $1.02 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here......»»

BioMarin (BMRN) delivered earnings and revenue surprises of 63.64% and -5.35%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 63.64%. A quarter ago, it was expected that this rare disease biopharmaceutical would post earnings of $0.30 per share when it actually produced earnings of $0.53, delivering a surprise of 76.67%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.BioMarin, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $408.74 million for the quarter ended September 2021, missing the Zacks Consensus Estimate by 5.35%. This compares to year-ago revenues of $476.78 million. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.BioMarin shares have lost about 16.3% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for BioMarin?While BioMarin has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for BioMarin was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.02 on $432.72 million in revenues for the coming quarter and $1.14 on $1.85 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Aflac (AFL) delivered earnings and revenue surprises of 17.69% and -2.72%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? Aflac (AFL) came out with quarterly earnings of $1.53 per share, beating the Zacks Consensus Estimate of $1.30 per share. This compares to earnings of $1.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 17.69%. A quarter ago, it was expected that this insurer would post earnings of $1.27 per share when it actually produced earnings of $1.59, delivering a surprise of 25.20%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.Aflac, which belongs to the Zacks Insurance - Accident and Health industry, posted revenues of $5.24 billion for the quarter ended September 2021, missing the Zacks Consensus Estimate by 2.72%. This compares to year-ago revenues of $5.67 billion. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Aflac shares have added about 28.5% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for Aflac?While Aflac has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Aflac was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.22 on $5.35 billion in revenues for the coming quarter and $5.61 on $21.7 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Insurance - Accident and Health is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Aflac Incorporated (AFL): Free Stock Analysis Report To read this article on Zacks.com click here......»»

United Rentals (URI) delivered earnings and revenue surprises of -3.24% and -0.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? United Rentals (URI) came out with quarterly earnings of $6.58 per share, missing the Zacks Consensus Estimate of $6.80 per share. This compares to earnings of $5.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.24%. A quarter ago, it was expected that this equipment rental company would post earnings of $4.81 per share when it actually produced earnings of $4.66, delivering a surprise of -3.12%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.United Rentals, which belongs to the Zacks Building Products - Miscellaneous industry, posted revenues of $2.6 billion for the quarter ended September 2021, missing the Zacks Consensus Estimate by 0.27%. This compares to year-ago revenues of $2.19 billion. The company has topped consensus revenue estimates three times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.United Rentals shares have added about 54% since the beginning of the year versus the S&P 500's gain of 21.8%.What's Next for United Rentals?While United Rentals has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for United Rentals was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $6.70 on $2.7 billion in revenues for the coming quarter and $21.77 on $9.66 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Building Products - Miscellaneous is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United Rentals, Inc. (URI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»